Mepolizumab vs omalizumab in severe asthma: is one better than the other?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In patients with severe asthma, mepolizumab (Nucala) appeared to be at least as effective as omalizumab (Xolair), with similar tolerability. 
Why this matters
  • There are no published comparisons of mepolizumab and omalizumab in patients with severe asthma.

Key results

  • Both drugs red...